Novoprotein(SH:688137) Zheng Quan Zhi Xing·2025-08-27 11:24Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. plans to use part of its oversubscribed funds amounting to RMB 72 million for permanent working capital, which represents 29.73% of the total oversubscribed funds, pending approval from the shareholders' meeting [1][5]. Fundraising Overview - The company raised a net amount of RMB 1,742.20 million from its initial public offering, with total oversubscribed funds amounting to RMB 242.20 million [2][4]. - The total investment amount for the fundraising projects is RMB 1,500 million, with the planned use of funds from this issuance also being RMB 1,500 million [2]. Plan for Using Oversubscribed Funds - The decision to use RMB 72 million of the oversubscribed funds for working capital is aimed at meeting the company's liquidity needs and improving the efficiency of fund usage, while ensuring that the fundraising projects continue as planned [2][3]. - The company commits that the cumulative use of oversubscribed funds for permanent working capital will not exceed 30% of the total oversubscribed funds within any twelve-month period [3][4]. Review and Approval Process - The board of directors and the supervisory board have approved the proposal to use part of the oversubscribed funds for working capital, which will be submitted for further approval at the shareholders' meeting [5]. - The supervisory board believes that the decision complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5].